甲基3-硝基-2-乙烯基苯甲酸酯 | 195992-04-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 甲基3-硝基-2-乙烯基苯甲酸酯
• 英文名称: methyl 2-ethenyl-3-nitrobenzoate
• 英文别名: methyl 3-nitro-2-vinylbenzoate；methyl 2-ethenyl-3-nitrobenzoic acid
• CAS: 195992-04-2
• 化学式: C₁₀H₉NO₄
• 分子量: 207.186
• InChiKey: XWAZRPUTQOQRRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  甲基3-硝基-2-乙烯基苯甲酸酯 在 盐酸 、 sodium tetrahydroborate 、 氯化亚砜 、 叠氮磷酸二苯酯 、 5%-palladium/activated carbon 、 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 溶剂黄146 、 乙酸乙酯 、 乙腈 为溶剂， 反应 72.0h， 生成 4-bromo-N-[8-ethyl-3-(1-pyrrolidinylmethyl)-7-quinolinyl]benzamide
  参考文献：
  名称：

  Melanin-Concentrating Hormone Receptor 1 Antagonists. Synthesis and Structure–Activity Relationships of Novel 3-(Aminomethyl)quinolines

  摘要：

  It was found that 3-(aminomethyl)quinoline derivatives showed high binding affinities for melanin-concentrating hormone receptor 1 (MCHR1) with reduced affinity for serotonin receptor 2c (5-HT2c) when the dihydronaphthalene nucleus of compound 1 (human MCHR1, IC50 = 1.9 nM; human 5-HT2c receptor, IC50 = 0.53 nM) was replaced by other bicyclic core scaffolds. Among the synthesized compounds, 8-methylquinoline derivative 5v especially showed high binding affinity (IC50 = 0.54 nM), potent in vitro antagonistic activity (IC50 = 2.8 nM) for MCHR1, and negligible affinity for 5-HT2c receptor (IC50 > 1000 nM). Oral administration of 5v significantly and dose-dependently suppressed nocturnal food intake in diet-induced obese rats and did not affect food intake in MCHR1-deficient mice. These results and rat pharmacokinetic study findings suggested that compound 5v is a highly potent, orally bioavailable, and centrally acting nonpeptide MCHR1 antagonist.

  DOI：

  10.1021/jm201596h
• 作为产物：
  描述：

  2-甲基-3-硝基苯甲酸甲酯 在 三乙胺 、 过氧化苯甲酰 作用下， 以 四氯化碳 、 二氯甲烷 、 氯仿 为溶剂， 反应 25.5h， 生成 甲基3-硝基-2-乙烯基苯甲酸酯
  参考文献：
  名称：

  SYNTHESIS OF INDOLES BY PALLADIUM-CATALYZED REDUCTIVE N-HETEROANNULATION OF 2-NITROSTYRENES: METHYL INDOLE-4-CARBOXYLATE

  摘要：

  DOI：

  10.15227/orgsyn.080.0075

文献信息

• Intramolecular cyclization reactions of unsaturated amino Fischer chromium carbenes forming indoles and quinolines
  作者：Björn C.G Söderberg、James A Shriver、Seth H Cooper、Timothy L Shrout、E Scott Helton、Lucinda R Austin、Herman H Odens、Brian R Hearn、Paula C Jones、Tiara N Kouadio、Tan H Ngi、Rachel Baswell、H John Caprara、Mark D Meritt、Than T Mai

  DOI：10.1016/j.tet.2003.09.028

  日期：2003.10

  annulation reaction of N-(2-alkenylphenyl)amino substituted Fischer chromium carbenes has been extensively examined. The carbene complexes were prepared in moderate to good yields by reaction of 2-aminostyrenes with intermediately formed acyloxy substituted carbenes. Upon heating, the thermally labile carbenes decomposed producing indoles and quinolines as the major products. The product distribution

  N-（2-链烯基苯基）氨基取代的费希尔铬卡宾斯的热诱导的分子内环化反应已得到广泛研究。通过2-氨基苯乙烯与中间形成的酰氧基取代的卡宾的反应以中等至良好的产率制备卡宾配合物。加热后，热不稳定的卡宾分解，生成吲哚和喹啉作为主要产品。发现产物分布高度取决于起始材料的取代模式和电子性质以及所用溶剂。
• Novel 4-anilinoquinoline-3-carboxamides
  申请人：——

  公开号：US20040248923A1

  公开（公告）日：2004-12-09

  The present invention relates to novel compounds of formula (IA), which are JAK3 Kinase inhibitors, methods for their preparation and pharmaceutical compositions comprising them.

  本发明涉及公式（IA）的新型化合物，它们是JAK3激酶抑制剂，以及它们的制备方法和包含它们的药物组合物。
• Quinoline compound
  申请人：Ishihara Yuji

  公开号：US20050209213A1

  公开（公告）日：2005-09-22

  A compound, which has a melanin-concentrating hormone antagonistic action and useful as an agent for preventing or treating obesity, and which is represented by the formula: wherein Ar is a cyclic group optionally having substituent(s); X is a bond or a spacer having a main chain of 1 to 6 atoms; R 1 and R 2 are the same or different and each is a hydrogen atom or a hydrocarbon group optionally having substituent(s), or R 1 and R 2 may form, together with the adjacent nitrogen atom, a nitrogen-containing heterocycle optionally having substituent(s); Y is a divalent hydrocarbon group optionally having substituent(s) (except CO); R 3 is a hydrogen atom or a hydrocarbon group optionally having substituent(s); and ring A and ring B may further have substituents, and when ring B further has a substituent, the substituent may be linked to R 1 to form a ring, or a salt thereof, or a prodrug thereof, is provided.

  一种化合物，具有黑色素浓缩激素拮抗作用，可用作预防或治疗肥胖症的药物，其化学式为：其中，Ar是一个环状基团，可以有取代基；X是1到6个原子的主链的键或空隙；R1和R2相同或不同，分别是氢原子或烃基，可以有取代基，或者R1和R2可以与相邻的氮原子一起形成含氮杂环，可以有取代基；Y是一个双价的烃基，可以有取代基（除CO）；R3是氢原子或烃基，可以有取代基；环A和环B还可以有取代基，当环B还有取代基时，取代基可以与R1连接形成一个环，或其盐，或其前药。
• 4-anilinoquinoline-3-carboxamides
  申请人：AstraZeneca AB

  公开号：US07037925B2

  公开（公告）日：2006-05-02

  The present invention relates to novel compounds of formula (IA), which are JAK3 Kinase inhibitors, methods for their preparation and pharmaceutical compositions comprising them.

  本发明涉及一种新型化合物（IA式），它们是JAK3激酶抑制剂，以及它们的制备方法和包含它们的药物组合物。
• QUINOLINE COMPOUND
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1447402A1

  公开（公告）日：2004-08-18

  A compound, which has a melanin-concentrating hormone antagonistic action and useful as an agent for preventing or treating obesity, and which is represented by the formula:    wherein Aris a cyclic group optionally having substituent(s) ; Xis a bond or a spacer having a main chain of 1 to 6 atoms; R1 and R2are the same or different and each is a hydrogen atom or a hydrocarbon group optionally having substituent(s), or R1 and R2 may form, together with the adjacent nitrogen atom, a nitrogen-containing heterocycle optionally having substituent(s); Yis a divalent hydrocarbon group optionally having substituent(s) (except CO); R3is a hydrogen atom or a hydrocarbon group optionally having substituent(s); and ring A and ring Bmay further have substituents, and when ring B further has a substituent, the substituent may be linked to R1 to form a ring, or a salt thereof, or a prodrug thereof, is provided.

  一种化合物，具有拮抗黑色素浓缩激素的作用，可作为预防或治疗肥胖症的药物，由式表示： 式中 Ar 是一个环状基团，可选择具有取代基； X 是主链为 1 至 6 个原子的键或间隔物； R1 和 R2 相同或不同，各自为氢原子或任选具有取代基的烃基，或 R1 和 R2 可与邻近的氮原子一起形成任选具有取代基的含氮杂环； Y 是可选具有取代基的二价烃基（CO 除外）； R3 是氢原子或可选具有取代基的烃基；以及 环 A 和环 B 可进一步具有取代基，当环 B 进一步具有取代基时，该取代基可与 R1 连接形成一个环、 或其盐或其原药。